Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jan Kitajewski
Columbia University Health Sciences, Department: Obstetrics & Gynecology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eisai Co., Ltd.
Other : Royalties received through the institution
Dr. Kitajewski is entitled to receive an inventor’s share of license fees and royalties through a license agreement between Columbia and Eisai. (Columbia’s Policy on Financial Conflicts of Interest and Research includes royalties above (b)(4), even if received through the University, in the definition of “significant financial interest.”) Dr. Kitajewski received a one-time share of up-front license payments of approximately (b)(4) within the past 12 months . Dr. Kitajewski continues to conduct research that relates to the NOTCH decoy technology covered by the license. In light of these facts, Columbia has determined that the outcome of this research could affect the value of the license and Dr. Kitajewski’s financial interest, and that the design, conduct, and/or reporting of this research could be affected by this financial interest.
Evaluating Notch Signaling as a Therapeutic Target in Ovarian Cancer
Ovarian cancer is the most fatal gynecologic malignancy because it is detected at late stages and frequently becomes resistant to chemotherapy. The Notch signaling pathway is a potential therapeutic target since it has been correlated with more aggressive ovarian cancers, correlated with chemotherapy resistance, and is involved in the development of blood vessels necessary for tumors to thrive. Therefore Notch signaling is a promising target in ovarian cancers, and may help reduce the fatality of this aggressive cancer.
Filed on February 10, 2015.
Tell us what you know about Jan Kitajewski's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jan Kitajewski”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jan Kitajewski | University of Illinois | Financial Disclosure | Rush Medical Center | |
| Jan Kitajewski | Columbia University Health Sciences | Conflict of Interest | Eisai Co., Ltd. | $40,000 - $59,999 |
| Jan Kitajewski | University of Illinois | Financial Disclosure | University of South Florida |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.